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INTRODUCTION 
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INTRODUCTION 
 
ISCHEMIC HEART DISEASE occurs when there is a mismatch 
between the myocardial oxygen supply and demand. Atherosclerosis 
involving the epicardial coronary arteries is the most common cause of 
ischemic heart disease, which decreases the perfusion and oxygen supply 
to the area of the myocardium supplied by that arterial territory. Ischemic 
heart disease poses a major economic burden both in the developed and 
as well as in the developing countries. Many factors like sedentary 
lifestyle, smoking, genetic factors, eating a high fat diet are associated 
with the new onset of ischemic heart disease.  
 
Aging is one of the non-modifiable risk factors for the ischemic 
heart disease. The WORLD HEALTH ORGANISATION estimated the 
average life- expectancy to be 73 years by the year 2025. The older 
population in the developing countries like ASIA is likely to double and 
will account for 10% of their populations [1].  GOYAL and YUSUF et al 
reported the prevalence of diabetes as 11.8% and 3.8% in the urban and 
rural areas respectively in the south Asia during the year 2006 [2]. 
Diabetes mellitus accounts for the 11.8% of myocardial infarctions by the 
INTERHEART STUDY [2]. 
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Prevalence of systemic hypertension is reported to be 20 – 40% 
and 12-17% respectively among the urban and rural population in INDIA 
[1]
.  
 
Systemic hypertension accounts for the 19.3% of myocardial 
infarctions by the INTERHEART STUDY[3]. It is estimated that26% of 
the adults are current smokers worldwide [4]. In India it is estimated that 
about 40 % of men are current smokers [5]. Tobacco usage is one of the 
modifiable risk factors for the ischemic heart disease. Elevated 
cholesterol levels accounts for the 56% of the ischemic heart disease and 
18% of strokes globally. Obesity is evolving as one of the major risk 
factors for ischemic heart disease globally. Obesity has been attributed to 
the life-style changes such as eating unhealthy foods, high fat diet, 
physical inactivity and the urbanization. 
 
Patients with ischemic heart disease are classified into two types.  
Two types include Patients with Coronary Artery Disease (CAD) who 
commonly presents with stable Angina and Patients with Acute Coronary 
Syndromes (ACSs). Patients with acute coronary syndromes comprise of 
patients who present with ST segment Elevation myocardial infarction, 
unstable angina and Non ST Elevation myocardial infarction. 
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Complications of myocardial infarction include ventricular 
dysfunction, cardiogenic shock, right ventricular infarction, arrhythmias, 
recurrent chest discomfort, pericarditis, thromboembolism, ventricular 
aneurysm and sudden cardiac death. 
 
Management strategies for unstable angina and Non ST elevation 
MI include medical treatment, anti ischemic treatment and antithrombotic 
therapy. Management of ST-ELEVATION MI include antithrombotic 
therapy, percutaneous coronary intervention, fibrinolysis, beta- 
adrenoreceptor blockers, Angiotensin converting enzyme inhibitors and 
supportive treatment include inotropic agents, vasodilators and diuretics 
for acute pulmonary edema, and anti-arrhythmics for arrhythmias. 
Secondary preventive measures include long term anti-platelet therapy 
with aspirin, or with clopidogrel in patients who are intolerant to aspirin. 
 
ACE Inhibitors, Angiotensin receptor blockers, aldosterone 
antagonists should be prescribed for patients with clinically evident heart 
failure, a moderate reduction in the ejection fraction or patients with large 
regional wall motion abnormality in order to prevent the ventricular 
remodelling after myocardial infarction. Management of risk factors is of 
utmost importance to prevent the future ischemic events.Finally 
rehabilitation is recommended for patients with advanced cardiac disease. 
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This study mainly focuses upon the baseline characteristics of 
patients with acute coronary syndromes (ACSs) and to assess the adverse 
outcomes such as Re-infarction, heart failure, dilated cardiomyopathy, 
arrhythmias, conduction disturbances, recurrent events and death in 
patients who got admitted to Rajiv Gandhi Government General Hospital 
with the diagnosis of acute coronary syndromes, so that further 
refinements in management can be done and patient’s survival and 
quality of life can be improved. 
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AIMS AND OBJECTIVES 
 
AIM 
Main aim is to assess the baseline characteristics of patients with 
acute coronary syndromes and to assess   the adverse outcomes in patients 
who present with acute coronary syndromes, so that management of 
patients with myocardial infarction can be made effective to prevent the 
recurrences. 
 
 
OBJECTIVES: 
 
A) To assess the cardiovascular morbidity and mortality in patients 
with acute coronary syndromes. 
 
B) To assess the prognosis of patients who presented with acute 
coronary syndromes during the follow up period of 6 months. 
 
C) To quantify the usefulness of baseline characteristics as prognostic 
factors in patients with acute coronary syndromes. 
 
D) To categorize the patients in the future so that strategies can be 
made to prevent the   future recurrences. 
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REVIEW OF LITERATURE 
 
THYGESEN et al [6].Defined   the diagnosis of Myocardial 
infarction in ESC (EUROPEAN SOCIETY OF CARDIOLOGY)expert 
consensus document that when any one of the following criteria are met 
along with the rise /fall of cardiac biomarkers. 
 
1. when the patient present with symptoms suggestive of ischemia, 
electrocardiographic changes suggestive of ischemia such as ST –T 
changes, new onset LBBB (left bundle branch block), appearances of 
pathological Q wave in electrocardiogram, imaging wise of loss of viable 
myocardium or regional wall motion abnormality along with the rise of 
cardiac biomarkers with at least one value above the 99th percentile of 
upper reference limit of normal. 
 
2. In   patients with unexpected death due to sudden cardiac arrest 
accompanied by symptoms of ischemia, and by Electrocardiographic 
(ECG) changes of ischemia, new onset of LBBB, evidence of fresh 
thrombus by coronary angiography, or occluded coronary thrombus 
during autopsy. 
 
3. For peri-procedural myocardial necrosis following percutaneous 
coronary intervention   the elevation of cardiac bio-markers especially 
creatinine kinase MB 3x URL (upper reference limit of normal). 
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4.  Following CABG (coronary artery bypass grafting) the diagnosis 
of myocardial infarction is suspected when there is 5x times elevation of 
the cardiac bio-markers of URL and coronary angiographic evidence of 
new coronary artery graft or native coronary artery occlusion. 
 
5. Pathological findings of acute myocardial infarction. 
 
Clinical features of myocardial ischemia: 
 
Term myocardial infarction denotes the death of cardiac myocytes 
due to the imbalance between oxygen demand and supply. Patients with 
myocardial ischemia present with symptoms of chest discomfort, diffuse 
chest pain which may radiate to inner aspect of left arm, jaw and usually 
accompanied by diaphoresis, palpitation, breathlessness, syncope and 
accompanied by sense of impending doom. 
 
Symptoms are non- specific because it can occur in an array of   
gastrointestinal, musculoskeletal, respiratory and neurological disorders. 
 Patients can present even without chest pain, due to silent ischemia in 
diabetics. Patient can present with ECG changes, elevation of cardiac bio-
markers or with imaging changes. 
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PATHOLOGICAL CHANGES IN PATIENTS WITH 
MYOCARDIAL INFARCTION: 
 
If the blood supply to the myocardium is restored within 30 
minutes the viability of myocardium can be restored. If there is a delay in 
Management beyond that reversibility period, Patient may develop 
myocardial necrosis mainly coagulative necrosis. Myocardial infarction 
can be classified pathologically based on the size. 
 
1. Small if < 10 % of the left ventricular myocardium is affected 
microscopically. 
2. Moderate when 10 – 30 % of LV myocardium is affected. 
3. Large when > 30 % of LV myocardium is affected. 
 
PHASES OF MYOCARDIAL INFARCTION PATHOLOGICALLY: 
1. EVOLVING PHASE- < 6 hrs. 
2. ACUTE PHASE- 6 hrs – 7 days. 
3. HEALING PHASE-7 – 28 days. 
4. HEALED PHASE – beyond 28 days. 
 
Timing of clinical symptoms, ECG changes may not correlate with 
Pathological changes. 
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CLINICAL CLASSIFICATION OF MYOCARDIAL INFARCTION [6] 
 
1. Type 1- spontaneous   myocardial infarction due to rupture of 
plaque, Plaque fissuring or erosion. 
 
2. Type 2- secondary to increased oxygen demand or decreased 
supply secondary to coronary embolism, coronary artery spasm, 
anemia, hypotension or hypertension. 
 
3. Type 3- In   patients with unexpected death due to sudden cardiac 
arrest accompanied by symptoms of ischemia, and by 
Electrocardiographic (ECG) changes of ischemia, new onset of 
LBBB, evidence of fresh thrombus by coronary angiography, or 
occluded coronary thrombus during autopsy but death occurring 
before blood samples could be obtained. 
 
4. Type 4a- Peri-procedural MI following percutaneous coronary 
intervention. 
 
5. Type 4b –myocardial infarction associated with stent thrombosis 
documented by angiography or at autopsy. 
 
6. Type 5- Myocardial infarction associated with Coronary artery 
Bypass grafting. 
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ECG CHANGES IN PATIENTS WITH MYOCARDIAL 
INFARCTION 
 
1. ST segment elevation in at least two contiguous leads with the 
voltage criteria of 0.2 mV in men and 0.15 in women in the 
precordialleads v2 and v3and 0.1 mV in other leads which is of new 
onset. 
 
2. ST segment depression and t wave changes with voltage criteria for 
ST segment depression being 0.05mV and 0.1 mV for t wave 
changes in atleast two contiguous leadswhich is of new onset. 
 
CARDIAC BIO-MARKERS: 
Cardiac bio-markers can be grouped into three [7]. 
1. Markers of myocardial ischemia. 
2. Markers of myocardial necrosis. 
3. Markers of cardiac damage/stress. 
 
Markers of myocardial ischemia include; 
a. H-FABP- HEART TYPE FATTY ACID BINDING PROTEIN. 
b. IMA- ISCHEMIA MODIFIED ALBUMIN. 
c. BNP- B-TYPE NATRIURETIC POLYPEPTIDE. 
d. NT-pro BNP- N-TERMINAL BNP. 
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Markers of cardiac necrosis: 
1. cTn- cardiac troponin. 
2. Ck-MB- creatinine kinase MB. 
3. Myoglobin.  
 
Markers of stress/stretch include: 
1. ADM- adrenomedullin. 
2. BNP/NT- pro BNP - B- type natriuretic polypeptide 
3. COPEPTIN- arginine vasopressin axis. 
4. GDF-15 growth differentiation factor 15. 
 
Although there are different class of cardiac bio-markers some 
markers are used for diagnostic and some markers are used for 
prognostication.  
 
Markers used for risk –stratification in myocardial infarction include 
1. BNP/NT- pro BNP. 
2. Growth differentiation factor -15. 
Several studies which utilised the BNP/NT pro BNP include for risk 
stratification in MI include. 
a. ACS, TIMI -16[8]. 
b. AMI- CONSENSUS [9]. 
c. NSTEACS [10]. 
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d. FRISC II[11]. 
e. TACTICS – TIMI -18[12]. 
Studies which utilized the GDF -15 as risk stratification in MI include. 
a. GUSTO IV [13]. 
b. ASSENT -2[14]. 
 
Though there are different biomarkers available in the market,   
Most widely used cardiac bio-marker is cardiac troponin.  
 
CkMB is used for the diagnosis of peri-procedural Myocardial      
Infarction, after percutaneous coronary intervention. 
 
 Patients with acute coronary syndromes can present with 
cardiogenic shock, ventricular dysfunction, arrhythmias, sudden cardiac 
death, thrombo-embolic events, recurrent chest discomfort, complete 
heart block, pericarditis, dilated cardiomyopathy, left ventricular 
aneurysm and ventricular septal rupture. 
 
1. Long term prognosis following myocardial infarction involving 
1000 subjects who had myocardial infarction 
wasstudiedretrospectively, from January 1983 – December 1987 by 
KYSMI STUDY GROUP [15]. Overall mortality due to cardiac 
causes was 5% and event rate was 35%. 
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2. Cardiac failure in a patient with acute coronary syndrome carries a 
poor prognosis [16]. 
3. The death rate among patients with unstable angina presenting with 
Heart failure is 4 x times higher when compared to patients without 
heart failure in unstable angina [17]. 
4. The GLOBAL REGISTRY OF ACUTE CORONARY EVENTS 
[GRACE][18] did a large observational study to assess the impact of 
in-hospital revascularization on survival in patients with NON ST 
elevation acute coronary syndrome and with congestive heart 
failure Between April 1999 and June 2007. 
The study involved 29, 844 patients with NON STEACS enrolled 
in 120 hospitals and about 4953 patients had congestive heart 
failure on presentation. In patients who presented with cardiac 
failure about 1/5th of them underwent revascularisation. 35 % of 
patients with cardiac failure were treated with medications based 
on evidence based medicine. They were followed up for a period of 
6 months, the death  rate was low in patients who underwent in- 
hospital revascularization in patients with NON-STEACS than 
when compared to patients who were managed conservatively, 
even after adjustment for GRACE risk score ,p < .005. 
A Statistically significant one and they suggested revascularization 
procedure for small proportion of patients with NONSTEACS. 
14 
 
5. Systemic hypertension is a known risk factor for the coronary 
artery disease [19, 20]. 
 
6. F. GUSTAFFSON, L.KOBER et al [21].  Conducted a study to 
assess the relationship of systemic hypertension on the prognosis of 
myocardial infarction. This study involved 6676 patients with 
myocardial infarction based on the survival data of patients who 
were screened for entry into TRAandolapril Cardiac Evaluation 
(TRACE) study. During the observation period 50.6% of 
hypertensives died compared to    43.7% normotensives.  Risk ratio 
of 1.3, mortality was more in patients aged >65 years. 
 
 
7. We all know that obesity is a risk factor for ischemic heart disease. 
Overweight is defined as BMI of >25kg/m2 and obesity is defined 
as BMI>30kg /m2 [22, 23].  Waist circumference of > 102 cm in men 
and > 88 cm in women are the risk factors for ischemic heart 
disease. 
 
8. In contrary to the belief that obesity is associated with an increased 
risk of ischemic heart disease. Studies have proven that it is not so, 
in contrary, it has an inverse relationship with cardiac disease. This 
is described as obesity paradox [24]. 
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9. ZELLER et al [25] studied a cohort of 2229 patients with acute 
myocardial infarction mainly to assess the relationship of obesity 
and mortality in patients with acute myocardial infarction. In the  
study group about 50% were overweight , 25 % were obese and 
about 50 % had increased waist circumference, in his cohort he 
reported that obesity was not significant predictor of mortality and 
raised waist circumference was also not a significant predictor of 
mortality. 
 
10.  This reversal relationship of obesity as a predictor of mortality is 
exhibited in patients with advanced heart failure and patients who 
are on Hemodialysis [26].  Patients with obesity have high metabolic 
reserve that safe guard them against inflammation which is seen in 
patients with acute myocardial infarction or heart failure 
[27]
.patients with BMI on higher side are at low risk of cardiac 
cachexia when compared to patients with normal BMI or 
overweight individuals.  
 
The neurohormonal profile i.e the B-Type natriuretic polypeptide 
level in patients with obesity is low, which is responsible for 
relatively a good prognosis when compared to patients with 
elevated B type natriuretic polypeptide.  
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11.  Regular exercise is being recommended in patients with heart 
failure and high BMI along with raised waist circumference, 
because exercise improves the local anti inflammatory activity and 
anti catabolic effects in skeletal muscle in addition to the reduction 
of visceral adipose tissue [28, 29, 30] . 
 
12. The relationship between alcohol and cardiovascular outcomes had 
been studied in different studies. 
 
13. The ONSET STUDY [31]. LYON DIET HEART STUDY [32],THE 
SURVIVAL AND THE VENTRICULAR ENLARGEMENT 
TRIAL [33], SHEEP STUDY [34] were the studies conducted to find 
out the association of alcohol with the long term prognosis 
following acute myocardial infarction. 
 
14. The conclusion of the SHEEP STUDY [34] was alcohol intake was 
associated with all cause cardiac mortality and morbidity after a 
myocardial infarction. Patients who quitted recently had the worst 
prognosis when compared to patients who had long term 
abstinence of alcohol.  
 
15. The relationship of alcohol with cardiovascular outcomes has been 
attributed to the favorable effect of alcohol on HDL –Cholesterol. 
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16. Alcohol intake decreases the fibrinogen level. It did notincrease the 
level of PAI-1 platelet activation inhibitor and tissue Plasminogen 
activator (tPA) [35].   
 
17. The association of diabetes mellitus with the ischemic heart disease 
has been clearly explained by the Framingham heart study [36, 37]. 
 
18.  I.GUSTAFFSON et al [38] conducted studies to find out                     
the association of long term prognosis of diabetic patients with 
myocardial infarction. 
 
19.  The mortality was 46.4% in non –diabetic populations during the 
follow up period of 7 years compared to 62.4% in diet treated 
diabetic populations. 
 
20. The mortality was 73.4% in patients treated with oral 
hypoglycemic agents when compared to 78.6 % in insulin treated 
diabetic patients which was statistically significant p<0.001. 
 
21. The heart failure incidence is more in diabetic patients when 
compared to non-diabetics. 
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22.  I.GUSTAFFSON et al [38] reported that 51.2% of non- diabetic 
population had heart failure as supposed to 72.3% in diabetic 
patients on meal plan. 66% of diabetics treated with oral 
hypoglycemic agents had heart failure compared to 72.1% of 
insulin treated diabetics, which was statistically significant P 
=0.001.  
 
23.  The mechanisms for heart failure in diabetics postulated are 
possibly due to less aggressive treatment in diabetics with 
thrombolytic agents and due to diabetes associated 
arteriolosclerosis affecting the small coronary vessels and 
myocardial fibrosis [39]. 
 
24.  DIGAMI [40, 41] study reported the cardiovascular mortality is less 
in diabetic patients who were treated intensively with insulin 
during the infarction and 3 months post myocardial infarction 
period. 
 
25. NATIONAL CHOLESTEROL EDUCATION PROGRAM AND 
ADULT TREATMENT PANEL III IN 2001(NCEP – ATP III)[42] 
Guidelines has put forth the criteria for metabolic syndrome as the 
presence of 3/5 of following criteria. 
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26. A. Abdominal obesity defined by the waist circumference of >102            
     cm in men and > 88cm in women. 
B. Triglyceride level of 150 mg/dL. 
C. HDL – cholesterol <40 mg/dL in men and < 50 mg/dL in  
     women. 
D. Fasting blood glucose of 110 mg/dL. 
E. Blood pressure of >130/85 mm hg. 
 
27. MARIANNE ZELLER et al [43] studied 633 patients who got 
admitted in the hospital for acute myocardial infarction, the author 
reported the prevalence of metabolic syndrome was 46%. 
 
28. Metabolic syndrome is common in patients who have both the 
DIABETES and SYSTEMIC HYPERTENSION .the prevalence 
was roughly varies between 35% and 80%. [44] 
 
29. The mortality rate in patients with metabolic syndrome was 2 fold 
higher when compared to patients without the metabolic syndrome. 
 
30. The heart failure was also more prevalent in patients with 
metabolic syndrome when compared to patients without the 
metabolic syndrome. 
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31. The heart failure has been attributed to the hyperglycemia in 
patients with metabolic syndrome and associated diastolic 
dysfunction due to diabetes mellitus. 
 
32.  CABADES, J.L DIEZ GIL et al [45]studied the relationship of 
gender differences with reference to the management and outcomes 
of acute coronary syndromes among 49 comprised of 38 men and 
11 women patients with   multi-vessel disease   underwent 
percutaneous intervention. There was no gender difference in the 
angiographic lesions and left ventricular function wise. The median 
survival among men was 34.4 months when compared to 24.7 
months in women. It was statistically significant p value =0.008. 
Female gender was found to have independent risk factor for 
predicting the mortality. 
 
33. M BLONDAL, T AINLAL et al [46]   assessed the relationship of 
reperfusion therapy and in – hospital mortality in patients with 
STEMI in Estoniain during 2001 versus 2007. About 2686 patients 
got hospitalized in the year 2001 when compared to 3483 patients 
in the year 2007. About 291 patients with STEMI were analyzed 
finally of which 129 patients during 2001 and 162 patients during 
2007 were studied. 
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34. About 42.6 % of patients were treated with reperfusion during 
2001 and 64.2% underwent reperfusion   during 2007. Among 
reperfusion patients about 35% patients were treated with 
thrombolysis during 2001 when compared to 7.0% during 2007. 
 
56.8% of patients underwent primary PCI versus 7.8%, after 
adjustment for age and sex   patients who underwent primary 
percutaneous intervention showed low in hospital mortality when 
compared to thrombolysis. 
 
35.    The incidence of arrhythmias in patients with STEMI treated with 
Percutaneous coronary intervention was studied by J 
KANOVSKY, P KALA et al [47] a sub-study of PROSPECT 
STEMI study. 
 
36. About 586 patients with STEMI during the 3 years were taken into 
study. About 45.2% patients had anterior wall myocardial 
infarction, Inferior wall myocardial infarction without right 
ventricular involvement was seen in 28.8% and 11.7 % patients 
had inferior wall with right ventricular involvement. 
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37. Malignant arrhythmias were noted in about 11.5% patients with 
inferior wall MI with right ventricular involvement compared to 
5.28 % in patients with anterior wall MI, which was statistically 
significant  p value  <0.05.  
 
Atrio-ventricular block was noted in 15.49% of patients with 
inferior wall myocardial infarction with right ventricular 
involvement   when compared to none in patients with anterior wall 
myocardial infarction which was statistically significant with p 
value <0.0001 . 
 
38. Guidelines recommend   CABG for patients with unprotected left 
main disease.  TAPIA BALLESTEROS, HERNANDEZ LUIS et al 
[48] compared the in –hospital mortality of patients with unprotected 
left main disease using PCI versus CABG. Mean age was around 
67%. About 50 patients were treated with CABG and 45 patients 
with worse clinical features at the time of admission were treated 
with percutaneous intervention. 23 % died during the hospital stay. 
The mortality during the 1 year post discharge follow up was 9% in 
PCI group compared to 0 % in CABG. Percutaneous coronary 
intervention is recommended for elderly patients with unprotected 
left main disease along with co- morbidities. 
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39.  P Milicevic, M panic et al [49]  studied the relationship between uric 
acid and mortality in patients with acute myocardial infarction they 
included about 912 patients with acute myocardial infarction. 
Patients were stratified into two sets, one with hyperuricemia and 
another without hyperuricemia. 
 
40. Patients were followed up for a period of 12 months and mortality 
among two groups was assessed.  Mortality was 36% in patients 
who had hyperuricemia when compared to 18.2% in patients 
without hyperuricemia. 
 
41.  P Vrsaloric, Getaldic B et al [50] assessed the prognosis of STEMI 
patients during the period January 2001 and December 2007. about 
543 patients STEMI patients  were assessed for 30 day mortality  
Utilizing    Hematocrit, C- reactive protein and fibrinogen levels.   
 
About 41% of patients of them died. By using univariate analysis 
hematocrit < 39% in men, hematocrit < 36% in women, CRP of 6.7 
Mg/L, Fibrinogen > 3.9 g/L were significantly associated With 
adverse outcome following STEMI and after adjustment forage, 
gender, cardiovascular risk factors anaemia and CRP had 
association with outcome of MI. 
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42.  J.M GARCIA –ACUNA, P AGUIAR SUOTOet al [51] did a study 
to assess the relationship between new onset atrial fibrillation and 
prognosis of myocardial infarction. About 1368 patients were 
followed up for a period of 14 months.   
 
New onset atrial fibrillation was found in 8% of patients and 
patients with atrial fibrillation had mortality of 11.4% compared to 
4.8% without atrial fibrillation. Ventricular tachycardia was found 
in 13.1% and heart failure was found in 48%. Using multivariate 
analysis atrial fibrillation of new onset was found to have 
significant association with adverse outcome following myocardial 
infarction. 
 
43.  R.L providencia, P.L Gomes et al [52] studied the relationship of 
admission blood glucose level and HbA1 c. about 212 patients 
were included  for the study .within 24 hours of admission blood 
glucose and HbA1 C were assessed. Patients were followed up for 
a period of 2 years.  42% of patients had hyperglycemia above the 
level of 140 mg/dl.  29.2 % patients had elevated HbA1C. After 
univariate and multivariate analysis hyperglycemia at admission 
had strong association with outcome after MI short term and 
HbA1C predicted the long term outcome in patients with acute 
myocardial infarction.   
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44. Gheorghe, I T NANEA et al [53]studied the complications in 
patients with ACUTE MYOCARDIAL INFARCTION between 
patients with ST ELEVATION MI and NON ST ELEVATION 
MI.  
 
About 238 patients werestudied. 60.5 % had ST elevation MI and 
39.5% patients had Non ST elevation myocardial infarction. 18% 
of them were in Killip class II and 8.4% were in Killip class III 
which was similar between the two groups. 17.36% of STEMI had 
ventricular tachycardia and ventricular fibrillation,Compared to 
2.12% of patients in NSTEMI group. 
 
45.  26.3% patients with STEMI died when compared to NSTEMI. 
The death rate in NSTEMI was 6.38%. 17.36% patients with ST 
elevation myocardial infarction had atrio ventricular block 2nd and 
3rd degree compared to 9.56 % patients with Non STelevation 
myocardial infarction.  
 
46. The conclusion of the study was ST elevation myocardial 
infarction was significantly more associated with the incidence of 
KILLIP class IV heart failure, ventricular tachycardia,ventricular 
fibrillation when compared to Non ST elevation myocardial 
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infarction. It was more so in patients who had previous myocardial 
infarction and heart failure. 
 
47. ASSANELLI, De Metrio et al [54] performed a study to assess the 
relationship of acute hyperglycemia with contrast induced 
nephropathy in patients with STEMI undergoing percutaneous 
intervention.  Percutaneous coronary intervention in diabetic 
patients with acute myocardial infarction during a planned 
procedure had a well known association with elevation of renal 
parameters if there is Co -existing diabetic nephropathy. They took 
those patients with acute hyperglycemia with acute myocardial 
infarction and its relationship with contrast induced nephropathy 
. 
48.  About 780 patients were included in the study .the criteria for 
acute hyperglycemia is blood glucose >198 mg/dl. and contrast 
induced nephropathy was defined as elevation of renal parameters 
of 25% above the baseline within 72 hours of administration of 
contrast. 19% of patients had acute hyperglycemia. 14.5 % of 
patients had contrast induced nephropathy. The risk of developing 
contrast induced nephropathy was 2 times higher in patients with 
acute hyperglycemia. The mortality in patients with contrast 
induced nephropathy was 27% when compared to 0.9% in patients 
without that complication. The mortality in patients with acute 
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hyperglycemia and contrast induced nephropathy was 38% 
compared to 0.5 % in patients without that complication. 
 
49. C.Fresco , M. de Biasio et al [55]  did a study to find out whether left 
anterior descending artery is the target artery in smokers. They 
studied 83 patients aged< 45 years. Among the 83 patients 72% 
were males. 
 
50. 64% of patients underwent percutaneous coronary intervention, 
17% of patients were treated with thrombolysis. The patients were 
followed up for a period of 40 months. 53% were active smokers. 
Single vessel disease was noted in coronary angiography in about 
68% of smokers and 65 % in non-smokers. In smokers left anterior 
descending artery was involved in about 55% of patients, 
circumflex was involved in about 19% of patients. Right coronary 
artery was involved in about 26% of patients.  
 
51.  Left anterior descending artery was involved in 42% of patients 
among non-smokers. There was no mortality during the follow up 
period of 40 months. The reason for the predilection of left anterior 
descending artery among smokers was not known when compared 
to former smokers. 
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52. M.J Garcia, Gonzalez et al [56] studied the impact of renal 
dysfunction on mortality in patients with acute myocardial 
infarction. About 150 patients who presented with renal failure 
along with myocardial infarction were included. GLOMERULAR 
FILTRATION RATE was estimated using COCKCROFT-GAULT 
formula. 125 patients had GFR > 60 ml/min and 25 patients had 
GFR < 60 ml/min. 
 
53. The mortality rate was 24% in patients with GFR < 60 ml/min 
when compared to 5.6% in patients with GFR > 60 ml/min. 
  
54. The renal dysfunction was strongly associated with in-hospital 
mortality in patients with renal dysfunction along with myocardial 
infarction at the time of admission.  
 
55. I. Rosario, H. Dores et al [57] studied the relationship between 
myocardial infarction and diabetes mellitus. A retrospective study 
was done to find out the baseline characteristics among patients 
with diabetes mellitus and   the type of myocardial infarction in 
those diabetics and the readmissions were assessed for a follow up 
period of 48 months. 
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56. Totally 587 patients were analyzed, 64% of them were males. 
29.8% patients had unstable angina.35.8% of patients had Non ST 
elevation myocardial infarction, 34.4 % of patients had ST 
elevation MI. 26.7% of the diabetic patients were treated with 
insulin. In-hospital mortality was about 15.3% in diabetic patients 
when compared to 7.9% in non diabetics. During the follow up at 6 
months diabetic patients had mortality 23.8% compared to 6.14% 
in non diabetics. At the end of 12 months the mortality rate among 
diabetics were 26.2% compared to 15.5% in non-diabetics, At the 
end of 24 moths mortality rates among diabetics was 28.6% 
compared to 16.3% in non diabetics. 
 
57.  The baseline characteristics and mortality was compared between 
STEMI and NSTEMI during the 5 year follow up period by C. 
Garcia –Garcia, I. Subirana et al [58] .about 2046 patients identified 
by RECATE II registry were analyzed, the proportion ofwomen, 
hypercholesterolemia, hypertension and diabetes were higher in 
patients among NSTEMI group patients. 34.6% of patients with 
NSTEMI underwent revascularization when compared to 21.7% in 
STEMI group. Surgical procedures were more commonly 
performed in NSTEMI group 14.4% compared to 7.4% in STEMI 
group. 
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58.  In –hospital mortality was low in patients with NSTEMI 
2.57%group when compared to STEMI group 5.94%. The 
mortality among NSTEMI group was 18.0% compared to 11.8% 
during the follow up of 5.6 years. 
 
59. The influence of prior CABG on mortality in patients with acute 
myocardial infarction was studied by the M. Panic, P.Milicevic et 
al [59].  
 
912 patients were studied and they were sub classified based on 
prior CABG and without CABG. About 55% patients had prior 
CABG. 
 
60. In patients with prior CABG diabetes was more prevalent 49% 
when comparedto 26.7% in patients without PRIOR CABG .left 
ventricular ejection fraction was 27.6 +12.7 in patients with prior 
CABG. It was low when compared to patients without PRIOR 
CABG. 
 
35.2+12.5.  Mean survival was 36.6% in patients with prior CABG 
compared to 44.2% in patients without prior CABG. Though 1 year 
mortality was more in patients with prior CABG, prior CABG was 
not found to be an independent predictor of mortality. 
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61. P. Serpytis, K. Rucinskas et al [60] studied the relationship between 
risk factors for surgery and in-hospital mortality in patients with 
acute coronary syndrome.   
 
62. About 246 patients were analyzed during  the period of Jan 2004 
and June 2009, patients were divided into two groups, those who 
have not survived and patients who were discharged. In-hospital 
rate mortality rate was 7.7%.  Patients who did not survive had 
higher prevalence of peripheral vascular disease, renal failure, and 
chronicobstructive pulmonary disease. When compared to patients 
who got discharged.CABG IN PATIENTS WITH ACUTE 
CORONARY SYNDROME has to be decided on the basis of risk 
stratification and the presence of co-morbid conditions. 
 
63. SamerThanavaro et al [61]studied the relationship of in-hospital 
mortality rate in patients with acute myocardial infarction on the 
basis of infarct location. 
 
64. About 1105 patients with transmural infarction were 
analyzed.55.3% had anterior wall myocardial infarction. 44.4% of 
patients had inferior wall myocardial infarction. Analysis of 
complications was done based on the infarct location. The 
mortality was low in patients with inferior wall 9.1% when 
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compared to 15.6 % in patients with anterior wall myocardial 
infarction. The   heart failure rates were low in patients with 
inferior wall myocardial infarction 39.4% compared to 47.6% in 
patients who had anterior wall infarction. 
 
65.  The cardiogenic shock rates were higher 12.6% in patients with 
anterior wall myocardial infarction when compared to 8.7% in 
patients with inferior wall myocardial infarction. The study 
concluded that infarct location was a strong independent predictor 
of adverse cardiovascular outcomes.  
 
66.  R.A .Providencia, J. Silva [62] assessed the mitral regurgitation role 
in patients with acute myocardial infarction. About 285 patients 
with acute myocardial infarction were taken for the study .about 
65.4% were men.40.6% of patients had diabetes mellitus. Patients 
were followed up for a period of 24 months. Mitral regurgitation 
was present in 44.6% of the patients. The predictors of mitral 
regurgitation were female gender, diabetes mellitus, Atrial 
fibrillation, left ventricular ejection fraction of 55%, age > 70 
years, Grace risk score of more than or equal to 140.  
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67. The presence of Atrial fibrillation, age more than 70 years, HbA1C 
Of more than or equal to 6.5% predicted the mortality after the 
follow up period of 24 months. 
 
68. R.Faria, J. Mimoso[63] did a study to assess the 6 month mortality 
rate among patients with STEMI versus NSTEMI. About 1332 
patients were included in the study. 
 
18 % of patients with ST Elevation myocardial infarction and 13% 
of patients with NON ST Elevation myocardial infarction could not 
participate in the study. 
 
69.  52 % of patients had ST Elevation myocardial infarction.48% of 
patients had NON ST Elevation myocardial infarction. They were 
followed up for a period of   6 months to assess the mortality. 17 % 
of the patients with ST Elevation myocardial infarction died 
compared to 14% in patients with NON ST Elevation myocardial 
infarction. The mortality rate was similar between the two groups 
at the end of 6 months. 
 
70. Sana M. Al-Khatib et al [64] conducted a study to find out the 
relationship between ventricular arrhythmias in NON ST Elevation 
Myocardial infarction with 30 day and 6 months mortality. 
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71. The patients were pooled from four different data sets. About 552 
number of patient had ventricular arrhythmias and 25, 864 patients 
did not have ventricular arrhythmias during the previous 
hospitalization. The independent predictors of ventricular 
tachyarrhythmia were prior  
 
Systemic hypertension, chronic obstructive pulmonary disease, 
prior myocardial infarction, and ST –T changes in the 
electrocardiogram. 
 
72.  At the end of 30 days the Hazard ratio for ventricular fibrillation 
was 23.2 and for ventricular tachycardia were 7.6. At the end of 6 
months the Hazard ratio for ventricular fibrillation was 14.8 and for 
ventricular tachycardia were 5.0. After the adjustment for 
cardiogenic shock or heart failure, both the ventricular tachycardia 
and ventricular fibrillation were associated with the 30 days and 6 
months mortality in patients with non ST elevation myocardial 
infarction. 
 
73.  Marino Labinazet al [65] studied the outcome of myocardial 
infarction in patients with prior CABG   versus without prior 
CABG. 
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The study population was selected from the PURSUIT trial. About 
1134 patients had prior CABG and 8321 patients did not undergo 
CABG previously. The Hazard ratio for patients with prior CABG 
was 1.45 at the end of 30 days .the hazard ratio for patients with 
prior CABG at the end of 180 days were 1.32. There was a similar 
relationship in the end point between eptifibatide treated Group 
versus placebo. 
  
  
 
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
 
STUDY DESIGN: 
 
1. Sample size             - 100 patients. 
 
2. Study population-the patients who got admitted to the RAJIV             
           GANDHI GOVERNMENT GENERAL HOSPITAL for acute  
           coronary syndrome. 
 
3. Type of study – cross sectional study. 
 
4. This study is a non-blinded and a Prospective study. 
 
5. Period of study- From MAY 2012 TO NOVEMBER 2012. 
 
6. The protocol of the study was approved by the Institutional Ethics              
          Committee, madras medical college, Chennai 600003. 
 
7. Written informed consent from all the 100 patients was obtained  
          prior to the enrollment in the study. 
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PATIENTS & METHODS 
Inclusion criteria: 
1. Study Population - patients admitted in Rajiv Gandhi Government  
    General Hospital for acute coronary syndrome. 
2. About 100 Patients aged between 18 years and 80 years,  
     Were Included for study. 
3.  Both male and female gender was taken up for this study.  
   
Exclusion criteria 
1. Patients with chronic stable angina. 
2. Patients with Rheumatic heart disease. 
3. Patients with congenital heart disease. 
4. Patients with aortic dissection/coarctation of aorta. 
5. Patients who underwent bio-prosthetic and mechanical valve  
          replacement surgeries.  
6. Patients with acute illnesses associate with CAD. 
7. Patients with diabetic ketoacidosisand non ketotic hyperosmolar  
          coma. 
8. Patients with known history of HIV 1/2, HEPATITIS B/C OR  
           SYPHILIS in addition to ACS. 
9. Patients with postpartum cardiomyopathy. 
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10. Patients below 18 and above 80 years. 
11. Patients with disorientation and unable to take part in the study. 
 
Study Conduct 
Number of patients: 100 
Methodology 
CASE DEFINITION: 
 
UA is defined as angina pectoris or equivalent ischemic discomfort 
with at least one of three features: (1) it occurs at rest (or with minimal 
exertion), usually lasting >10 minutes; (2) it is severe and of new onset 
(i.e., within the prior 4–6 weeks); and/or (3) it occurs with a crescendo 
pattern (i.e., distinctly more severe, prolonged, or frequent than 
previously).  
 
The diagnosis of NSTEMI is established if a patient with the 
clinical features of UA develops evidence of myocardial necrosis, as 
reflected in elevated cardiac biomarkers. 
 
Criteria for ST SEGMENT ELEVATION 
ST segment elevation in at least two contiguous leads with the 
voltage criteria of 0.2 mV in men and 0.15 in women in the precordial 
leads v2 and v3 and 0.1 mV in other leads which is of new onset. 
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CARDIAC BIOMARKERS: 
CK- MB normal value is 0.0-5.5 ng/ml. 
ECHOCARDIOGRAPHY: 
Ejection fraction 2D: 1. ≥ 55%   = Normal LV systolic function. 
                                  2. 45 -54% = Mild systolic dysfunction. 
                                  3. 30- 44% = Moderate systolic dysfunction. 
                                  4. ≤ 29%    = Severe LV dysfunction.     
 
METHODOLOGY 
1. Based on inclusion and exclusion criteria about 100 patients were 
included in the study. 
2. Written informed consent from the eligible patients or their legal 
representatives was obtained after explaining the full details of the 
study. 
3.  The data of the patients were collected with the help of structured 
questionnaire, which was filled up after interviewing the patients or 
his/her family members.  
4. Basic Laboratory investigations which include Complete Blood 
Count, Renal Function Tests, Random Blood Sugar, liver function 
tests, were obtained from all patients. 
5. Cardiac bio-markers, fasting lipid profile, Electrocardiogram, 
Echocardiogram, during the time of admission were obtained. 
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6. Coronary angiogram, percutaneous coronary intervention and 
Coronary Artery Bypass Grafting were performed based on the 
clinical profile of the individual patients.  
7. Baseline characteristics of the acute coronary syndrome were 
noted. Patients were observed for the major adverse cardiovascular 
outcomes such as complications during the admission for acute 
coronary syndrome and post discharge.   
8. Those patients who got admitted for acute coronary syndrome are 
followed up regularly over a period of 6 months from May 2012 
and November 2012 for adverse cardiovascular outcomes. 
9. The major adverse cardiovascular outcomes looked for were   re- 
infarction, cardiac failure, arrhythmias such as atrial fibrillation, 
ventricular tachycardia, ventricular fibrillation, sinus node 
dysfunction, atrioventricular conduction blocks, ischemic dilated 
cardiomyopathy, cardioembolic stroke, ventricular septal rupture, 
post infarction angina and death. 
10. The patients were consulted regarding any re admission for 
cardiovascular events and other non-cardiac illnesses. The details 
of the intervention such as percutaneous coronary Intervention 
pacemaker insertion for conduction disturbances and Coronary 
Artery Bypass Grafting were noted. 
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11. Data was compiled and the Statistical analysis of the collected data 
was done. 
 
STATISTICAL ANALYSIS 
Descriptive statistics were used for presenting the patient 
characteristics. All data would be subjected to FISHER’S EXACT TEST 
and UNPAIRED ‘t’ test. Individual group comparisons would be made 
using parametric tests and non-parametric tests as appropriate. P value of 
<0.05 is taken as significant in this study. Statistical analysis was done 
with GRAPH PAD PRISM software. 
 
 
 
 
 
 
 
 
  
 
 
OBSERVATIONS AND ANALYSIS 
  
 OBSERVATION AND ANALYSIS
GENDER DI
MALES
 
GENDER DISTRIBUTION IN PATIENTS WITH ACS
 
 
Gender distribution in patients with ACS
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TABLE 1 
STRIBUTION IN ACUTE CORONARY 
SYNDROMES PATIENTS 
 
 
 
FEMALES
 
89% 
 
11%
 
CHART-1 
 
89%
11%
males females
 
 
 
 
 
 AGE IN RELATION WITH ACUTE CORONARY SYNDROME
 
21-30  
YEARS 
31-40 
YEARS
 
3 
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AGE DISTRIBUTION IN PATIENTS WITH ACS
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AGE DISTRIBUTION IN PATIENTS WITH ACS
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TABLE-2 
 
 
41-50 
YEARS 
 51-60 
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61-70 
YEARS
 
      29 
 
40 
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CHART-2 
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61-70 
YEARS
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 DURATION OF SYMPTOMS
ACUTE CORONARY SYNDROMES
S.NO DURATION OF 
SYMPTOMS
1. 0-3 HOURS
2. 4- 6 HOURS
3. 7 – 12 HOURS
4. 13-24 HOURS
5. 2 – 4 DAYS
6. 5- 7 DAYS
7.  >7 DAYS
 
DURATION OF SYMPTOMS IN PATIENT
DURATION OF SYMPTOMS
N
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A
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N
T
S
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TABLE-3 
 IN PATIENTS PRESENTED WITH
 
 
NUMBER OF 
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DURATION OF SYMPTOMS
 
PEOPLE 
5 
 
8 
9 
 
 
1 
ACS 
 
5-7 
DAYS
> 7 
DAYS
11 1
 DIABETES AND IT’ S RELATIONSHIP TO
DIABETES
37%
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TABLE-4 
ACUTE 
CORONARY SYNDROME 
 NO  DIABETE
 63%
CHART-4 
DIABETES AND ACS 
 
DIABETES
37%
NO DIABETES
63%
DM AND ACS
 
S 
 
 
 SYSTEMIC HYPERTENSION AND 
HYPERTENSIVES
47%
 
 
SYSTEMIC HYPERTENSION AND ACS
 
 
 
 
47%
HYPERTENSIVES
SYSTEMIC HYPERTENSION AND ACS
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TABLE-5 
ACUTE CORONARY
SYNDROMES 
 NORMOTENSIVES
 
 
 
53% 
CHART-5 
 
53%
NORMOTENSIVES
PERCENTAGE
 
 
 
 
 FAMILY HISTORY OF CAD IN ACS PATIENTS
 
 
FAMILY HISTORY OF CAD
 
 
 
 
FAMILY HISTORY OF CAD and ACS
 
TOTAL NO  
OF  
PATIENTS 
 
 
100 
 FATHER
 
     8
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TABLE 6 
CHART-6A 
 AND ACS
17%
83%
FAMILY H/O CAD NO FAMILY H/O CAD
FAMILY HISTORY OF CAD 
17 
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FAMILY           
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 FAMILY HISTORY OF CAD AND ACS
 
 
MOTHER
BROTHER
SISTER
FATHER MOTHER BROTHER
8 7 1
FAMILY H/O CAD
 
 
SISTER
1
 PREEXISTING CAD IN PATIENTS WITH ACS
 
1. 
 
2. 
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TABLE-7 
 
PRIOR CAD 
 
NEW ONSET 
CHART-7 
PRIOR HISTORY OF CAD 
 
48%
52%
Pre existing CAD and ACS
 
 
48% 
 
52% 
 
PRIOR CAD
NEW CAD
 DISTRIBUTION OF BMI
NORMAL BMI
 
                    59 
 
    
MALES 
 
FEMALES
        56          3 
 
DISTRIBUTION OF BMI IN ACS PATIENTS
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DISTRIBUTION OF BMI IN ACS PATIENTS
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TABLE-8 
 AMONG PATIENTS WITH ACUTE 
CORONARY SYNDROMES 
 
OVERWEIGHT 
INDIVIDUALS 
OBESE  PEOPLE
 
                       36 
 
                
 
  
MALES 
FEMALES MALES
     29        7        4 
CHART-8 
 
OVERWEIGHT
56 29
3 7
 
       5 
 FEMALES 
      1 
 
 
OBESE
4
1
 WAIST CIRCUMFERENCE
 
 
MEN > 102 CMS
14 OUT OF 8
 
WAIST CIRCUMFERENCE
 
 
 
RAISED WAIST CIRCUMFERENCE IN PATIENTS 
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TABLE-9 
 IN CMS
 
 
WOMEN > 88 CMS
9 9 OUT OF 
 
CHART 9 
 AND IT’S RELATION WITH ACS
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9/11 FEMALES
WITH ACS
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SMOKING
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TABLE 10 
SMOKING AND ACS 
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SMOKING AND ACS 
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SMOKING AND ACS
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 RELATIONSHIP OF AL
ACUTE 
 
S.NO 
 
ALCOHOLISM
 
 
1. 
 
 CONTINUED 
ALCOHOL 
CONSUMPTION
 
2. 
 
PREVIOUS 
ALCOHOL INTAKE 
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ALCOHOL INTAKE AND ACS
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TABLE-11 
COHOLISM IN PATIENTS WITH 
CORONARY SYNDROMES 
 
 
ST- 
ELEVATION 
MI 
 
NON ST
ELEVATION 
MI 
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CHART 11 
 OF ALCOHOL IN PATIENTS WITH 
CONTINUED ALCOHOL 
CONSUMPTION
PREVIOUS ALCOHOL INTAKE
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5
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3
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 ACUTE CORONARY SYNDROMES
 
ST- ELEVATION
 
31 
 
ACUTE CORONARY SYNDROME
 
 
STEMI
31%
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TABLE-12 
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NON ST-
ELEVATION MI 
UNSTABLE 
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CHART-12 
 
 
 
NSTEMI
UNSTABLE ANGINA
12%
57%
ACS
ACS
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 SYSTOLIC FUNCTION IN PATIENTS WITH ACS
 
NORMAL SYSTOLIC 
FUCTION  
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NORMAL SYSTOLIC 
FUNCTION
GRADING OF SYSTOLIC DYSFUNCTION IN 
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TABLE-13 
 
   DECREASED EJECTION FRACTION
MILD 
DYSFUNCTION 
MODERATE 
DYSFUNCTION
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CHART-13 
SYSTOLIC FUNCTION IN ACS 
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MODERATE SYSTOLIC 
DYSFUNCTION
40
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PATIENTS WITH ACS
NUMBER OF PATIENTS
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 DIASTOLIC FUNCTION IN PATIENTS WITH ACUTE 
S.NO DIASTOLIC 
FUNCTION
 
    1. 
 
NO 
DYSFUNCTION
 
    2. 
 
GRADE 1 
DYSFUNCTION
 
    3. 
 
GRADE 2 
DYSFUNCTION
 
     4. 
 
GRADE 3 
DYSFUNCTION
 
DIASTOLIC FUNCTION IN ACS
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NSTEMI
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DIASTOLIC FUNCTION IN ACS PATIENTS
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TABLE-14 
CORONARY SYNDROMES 
 
ST-
ELEVATION 
MI 
NON 
ST-ELEVATION 
MI 
 
 
             17 
 
           6 
 
 
              6 
 
            4 
 
 
               3 
 
             2 
 
 
              16 
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CHART-14 
 
NO 
DYSFUNCTIO
N
GRADE1 
DYSFUNCTIO
N
GRADE 2 
DYSFUNCTIO
N
33 2 3
6 4 2
17 6 3
UNSTABLE  
ANGINA 
 
               33 
 
                2 
 
                3 
 
                 1  
 
GRADE  3 
DYSFUNCTIO
N
1
7
16
 MITRAL REGURGITATION 
 
                  NO MR 
 
68 
 
MITRAL REGURGITATION AND ACS
 
 
 
NO MR
MITRAL REGURGITATION IN ACS PATIENTS
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TABLE-15 
IN PATIENTS WITH ACUTE 
CORONARY SYNDROMES 
 
              MILD  MR 
 
MODERATE MR
 
26 
 
CHART-15 
 
MILD MR
MODERATE MR
68%
26%
6%
PERCENTAGE
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 COMPLICATIONS IN PATIENTS WITH ACS DURING THE 
SERIAL 
NUMBER 
1 DILATED 
CARDIOMY
2 UNSTABLE ANGIN
3 CARDIAC FAILURE
4 ATRIAL FIBRILLATION
5 VENTRICULAR 
TACHYARRYTHMIAS 
6 COMPLETE HEART BLOCK 
7 MOBITZ TYPE 2 BLOCK
8 SA NODE DYSFUNCTION
 
4
COMPLICATIONS IN ACS PATIENTS
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TABLE-16 
FOLLOW UP 
COMPLICATIONS TOTAL NUMBER 
OF PATIENTS
OPATHY 
A 
 
 
 
 
 
 
CHART 16 
COMPLICATIONS IN ACS 
6
14
3
2 2
NUMBER OF PATIENTS
 
4 
6 
14 
3 
2 
2 
1 
1 
 
1 1
 NUMBER OF PATIENT
SINGLE VESSEL 
DISEASE 
9 
 
 
CAG ABNORMALITIES IN PATIENTS WITH ACS
 
 
CAG ABNORMALITIES IN ACS PATIENTS
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TABLE-17 
S WITH CAG ABNORMALITIES
DOUBLE VESSEL 
DISEASE 
TRIPLE VESSEL 
DISEASE
16 
CHART-17 
 
SINGLE 
VESSEL 
DISEASE
25%
DOUBLE VESSEL 
DISEASE
44%
TRIPLE VESSEL 
DISEASE
31%
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 BASELINE CHARACTERISTICS OF PATIENTS WITH 
CORONARY ANGIOGRAPHIC ABNORMALITIES
 
S.NO 
 
DEMOGRAPHIC 
DATA 
1 MALES 
2 FEMALES  
3 DIABETES 
MELLITUS 
4 
 
SYSTEMIC 
HYPERTENSION
5 PRIOR  CAD
6 FAMILY HISTORY 
OF CAD 
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UNSTABLE ANGINA
CAG ABNORMALITIES AND BASELINE 
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TABLE-18 
 
SINGLE  
VESSEL 
DISEASE 
DOUBLE 
VESSEL 
DISEASE 
            5            14 
             1              2 
             4              8 
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              5              6 
             2              6 
CHART-18 
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 CORONARY ANGIOGRAM ABNORMALITIES IN
WITH ACUTE CORONARY SYNDROMES
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CORONARY 
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CORONARY ANGIOGRAPHIC ABNORMALITIES 
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TABLE-19 
 
SINGLE 
VESSEL 
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VESSEL 
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IN PATIENTS WITH ACS
 PATIENTS 
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 RELATIONSHIP OF RISK FACTORS OF ACUTE CORONARY 
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TABLE-20 
SYNDROMES 
CHART-20 
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SYSTEMIC 
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H/O CAD
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          7 
 
           11 
 
          6 
 
            6 
 
          26 
 
            35 
 
CAD
6
4
38
FAMILY 
HISTORY 
OF CAD 
PRIOR 
CAD 
 
            4 
 
         6 
 
             0 
 
         4 
 
           13 
 
        38 
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DISCUSSION 
 
1. 89% of patients were males, 11% were females. Males had 
increased incidence of acute coronary syndromes. 
 
2. Patients in the age group of 51-60 years had increased incidence of 
acute coronary syndrome. Patients with young myocardial 
infarction as defined by age <45 yrs constituted about 19%.Rabih 
R Azar et al [66] reported that the age limit for defining young 
patients as between 40 – 45 years. Diabetes had a strong 
association in this study which is statistically significant p <0.008.  
Smoking did not have significant association in this study. p=0.06. 
Probably further stratification of smoking is needed to prove the 
association. 
 
3. Complications were less in patients with young MI compared to 
patients aged > 45 year which was statistically significant. P 
<0.005.No deaths were noted in patients with young myocardial 
infarction. 
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TABLE 21 
COMPARISONS BETWEEN PATIENTS WITH MI 
AGED LESS THAN 45 YRS AND MORE THAN 45 YRS 
 
CHARACTERISTICS MI IN 
PATIENTS 
AGED< 45 
YEARS 
(n= 19) 
MI IN 
PATIENTS 
AGED > 45 
YEARS 
(n= 81) 
P VALUE 
AGE 38.31± 6.52 57.33± 8.02 0.0001*** 
DIABETES MELLITUS 2 35 0.008** 
HYPERTENSION 6 41 0.2  ns 
SMOKING 15 43 0.06 ns 
FAMILY H/O CAD 3 14 1.0  ns 
COMPLICATIONS 0 32 0.005** 
DEATH 0 5 0.5 ns 
  
*** - extremely significant, ** - significant,  
ns-not significant 
 
4. In comparison of MI in patients with hypertension and 
normotension, patients with hypertension had significant 
association with PRIOR CAD. MI patients with hypertension had 
higher ejection fraction when compared to patients with 
normotension which was statistically significant p value 0.001. 
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TABLE- 22 
COMPARISONS OF BASELINE CHARACTERISTICS IN 
HYPERTENSIVES AND NORMOTENSIVES AMONG MI 
PATIENTS 
CHARACTERISTICS HYPERTENSIVES 
(n=47) 
NORMO-
TENSIVES 
(n=53) 
PVALUE 
DM 18 19 0.8ns 
PRIOR CAD 28 20 0.04 * 
EJECTION 
FRACTION 
48.85+ 10.02 42.55+8.94 0.001** 
CARDIAC 
COMPLICATIONS  
14 19 0.5 ns 
 
*- quite significant, ** - significant, ns-not significant  
 
5. In MI patients with diabetes and no diabetes, diabetes had 
significant association hypertension which was statistically 
significant p =0.0001. 
 
6. DIABETIC MI population was strongly associated with prior CAD 
which was statistically significant p =0.03.Diabetes patients had no 
statistically significant association with systolic dysfunction, 
diastolic dysfunction and complications in this study. 
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TABLE 23 
COMPARISONS BETWEEN MI IN PATIENTS WITH  
DIABETES AND NO DIABETES 
CHARACTERISTICS DIABETES 
MELLITUS 
(n=37) 
NO 
DIABETES 
MELLITUS 
(n=63) 
PVALUE 
HYPERTENSION 7 40 0.0001 *** 
PRIOR CAD 23 25 0.03* 
EJECTION 
FRACTION 
49.20±12.04 50.42±10.56 0.6 ns 
DIASTOLIC 
DYSFUNCTION 
19 25 0.2 ns 
COMPLICATION 15 18 0.2 ns 
 
*- quite significant, *** - extremely significant, 
ns -not significant 
 
7. The relationship between AWMI and smoking was studied. There 
was no correlation between smoking and anterior wall MI in this 
study. 
 
8. C.Fresco, M. de Biasio et al [55] reported association between 
smoking and anterior wall MI (LAD involvement).The present 
study had no association. Probably further stratification and larger 
sample size is needed to prove the association. 
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TABLE 24 
COMPARISON OF ANTERIOR WALL MI AND SMOKING        
IN PATIENTS WITH MI 
CHARACTERISTICS AWMI 
n=18 
NON  
AWMI 
n=82 
P VALUE 
SMOKERS 10 48 
1.00 ns NON SMOKERS 
8 34 
 
   ns- not significant 
 
9. Family H/O CAD was present in 17 % of the patients. Prior CAD 
was present in 48% of the patients.  
 
10. UNSTABLE ANGINA constituted about 57%, STEMI constituted 
about 31 % of patients with ACS. NSTEMI constituted about 12% 
of Patients with ACS. 
 
11. All patients had type I myocardial infarction based on clinical 
classification of MI [6]. 
 
12. About 60 % of patients had systolic dysfunction and 44% of the 
patients had diastolic dysfunction. 
 
13. 32% of the patients with ACS had mitral regurgitation. 
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14. 33% of the patients with ACS complications, the details are 
measured in TABLE 14. The complications include cardiac failure, 
dilated cardiomyopathy, unstable angina happened in about18% of 
patients. tachyarrythmias which include atrial fibrillation and 
ventricular tachycardia occurred in about 15% of patients. 
 
15. Bradyarrythmias which include SA node dysfunction (for which 
patient underwent permanent pacemaker insertion) and atrio 
ventricular block happened in about 12% of patients. 
 
16. Patients with inferior wall MI had conduction disturbances when 
Compared to anterior wall MI which was statistically significant 
p=0.0003. 
 
17. J KANOVSKY, P KALA et al [47]  that patients with inferior wall 
MI was associated with conduction disturbances and more  so the 
association is more with inferior wall and right ventricular 
involvement. 
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TABLE 25 
CONDUCTION DISTURBANCES IN PATIENTS WITH 
INFERIOR WALL MI AND AWMI 
CHARACTERISTICS CONDUCTION 
DISTURBANCES 
(n=4) 
NO  
CONDUCTION 
DISTURBANCES 
(n=96) 
P 
VALUE 
IWMI 4 11 0.0003 
*** 
NO IWMI 0 85 
 
*** - extremely significant 
TABLE 27 
CARDIAC BIOMARKERS CK MB IN PATIENTS WITH STEMI 
AND NSTEMI 
 
ST ELEVATION MI (n= 31) NON ST ELEVATION MI (n = 12) 
MEDIAN 424.03IU/ml. MEDIAN 536IU/ml. 
 
MEDIAN ck MB was higher among patients who had NSTEMI 
when compared to STEMI. 
18. Coronary angiographic abnormalities were present in about 37% of 
patients with ACS. Single vessel involvement was involved in 9 
patients, double vessel disease was present in 16 patients and triple 
vessel disease was noted in 12 patients. 
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19. About 9 patients underwent percutaneous coronary intervention 
and 4 patients underwent CABG. 
 
20. Complications were nil in patients who underwent percutaneous 
intervention compared to no PCI which was statistically significant 
p=0.02. Death rate was not significant between PCI and no PCI 
.due to the small sample of the intervened group. A larger sample 
size is necessary to compare the association between the mortality 
and PCI. 
TABLE 28 
COMPARISONS BETWEEN PCI AND NO PCI GROUP 
 
*- quite significant, ns- not significant 
 
21. There was no significant association between complications and 
mortality between CABG and NO CABG group, which is probably 
due to the small sample size. 
  
CHARACTERISTICS PCI 
(n=9) 
NO PCI 
(n=91) 
P VALUE 
COMPLICATIONS 0 33 0.02* 
DEATH 0 5 1.00 ns 
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TABLE 29 
COMPARISONS BETWEEN CABG AND NO CABG GROUP 
CHARACTERISTICS CABG 
(n=4) 
NO CABG 
(n=96) 
P VALUE 
COMPLICATIONS 1 32 1.00 ns 
DEATH 1 4 0.18 ns 
  ns- not significant 
22. In patients with intervention which include PCI and CABG group 
prior CAD is associated with the prognosis and no difference were 
noted in other parameters such as systolic function, complications, 
mortality due to small sample size. 
TABLE 30 
COMPARISONS BETWEEN INTERVENTION AND NO 
INTERVENTION GROUP 
 
      *-quite significant, ns – not significant 
CHARACTERISTICS INTERVENTION 
(n =13) 
NO 
INTERVENTION 
(n=87) 
P 
VALUE 
DM 4 33 0.7 ns 
HYPERTENSION 6 41 1.00 ns 
PRIOR CAD 10 38 0.03 * 
EJECTION 
FRACTION 51.35±9.425 49.97±10.75 0.6 ns 
COMPLICATIONS  4 29 1.00 ns 
DEATH 1 4 0.5 ns 
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23. About 5% patients with ACS died during the follow up period of 6 
Months. The complications rate among patients in mortality group 
versus no mortality was statistically significant p value 0.0032. 
 
24.  There was an association between mortality and PRIOR CABG 
which was statistically quite significant between died and survived 
patients. p=0.05 
 
TABLE 31 
COMPARISONS BETWEEN MORTALITY AND SURVIVAL 
AMONG PATIENTS WITH ACS 
CHARACTERISTICS DEATH (n=5) 
NO DEATH 
(n=95) P VALUE 
DM 2 35 1.00 ns 
HYPERTENSION 2 45 1.00 ns 
PRIOR CAD 4 44 0.1 ns 
BMI 24.20±3.92 23.87±4.90 0.8 ns 
EJECTION 
FRACTION 49.62±11.29 49.97±10.75 0.9 ns 
COMPLICATION 5 28 0.0032 
*** 
PRIOR CABG 1 0 0.05* 
 
*- quite significant,***-extremely significant, ns-not significant 
 
  
 
 
CONCLUSIONS 
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CONCLUSION 
 
1. Males had increased incidence of acute coronary syndrome, about 
89% when compared to females 11%. 
 
2. About 8% of patients aged less than 45 years had myocardial 
infarction. 
 
3. DM was significantly associated with MI among patients aged less 
than 45 years. 
 
4.  Patients with young MI had good prognosis. 
 
5. Diabetes mellitus and Systemic hypertension was strongly 
associated with prior CAD. 
 
6.  Mean ejection fraction was higher in patients with hypertension 
compared to normotension. 
 
7. There was no correlation between smoking and anterior wall 
myocardial infarction in this study. 
 
8. History of PRIOR CAD was present in about 48% of the patients. 
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9. Unstable angina was more prevalent among patients with ACS. 57 
% of patients had UNSTABLE ANGINA, 31% had STEMI and 12 
% had NSTEMI.  
 
10. 60 % of patients with ACS had systolic dysfunction. 
 
11. 44 % of patients with ACS had diastolic dysfunction. 
 
12. Inferior wall MI was strongly associated with conduction 
disturbances when compared to patients with AWMI. 
 
13. Coronary angiographic abnormalities were present in 37% of ACS 
patients, 9 had Single vessel disease, 16 had double vessel disease, 
12 had triple vessel disease. 
 
14. 9% of the patients underwent PCI, 4% underwent CABG and 1 
patient with prior CABG died. 
 
15. Complications following ACS occurred in about 33% of the 
patients. 
 
16. Mortality rate was 5% in patients with ACS. 
 
17. No complications occurred in patients who underwent PCI. 
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18. No significant association observed among complications and 
death in patients between CABG and NO CABG. 
 
This study is done to find out the characteristics of patients with 
ACS admitted in our hospital. Many patients are getting admitted 
again for recurrent chest pain and other complications to our 
hospital. This study highlighted the baseline characteristics and 6 
months prognosis follow up among ACS patients in our hospital. 
With this information improvement can be made in managing 
patients with ACS and thereby complications can be reduced and 
reducing the economic burden of the patients as well as for 
country. 
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STUDY LIMITATIONS 
 
1. Sample size was smaller to compare the baseline characteristics 
among ACS patients. If sample size was larger more association 
can be made out.  
 
2. Further stratification among diabetic patients regarding the oral 
hypoglycemic agents and insulin is necessary, for deriving detailed 
prognosis following ACS among those patients,   those details   
were lacking in the present study. 
 
3. Stratification of smoking is needed to prove the association 
between AWMI and smoking. 
 
4. Prognosis of MI patients based on cardiac biomarkers, cardiac 
Troponin need to be done that is lacking in the present study, due 
to unavailability of troponin assays in our hospital. 
 
5. More intervention needs to be done among patients with ACS that 
was lacking in the present study due to financial constraints. 
 
6. Prognosis between PRIOR CABG and NO PRIOR CABG patients 
can be made, more number of patients with CABG have to be 
included in the study. 
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FURTHER STUDIES 
 
1. Prognosis can be made based on uric acid levels in patients with 
ACS. 
 
2. Prognosis based on recent cardiac biomarkers like BNP, NT pro 
BNP can be made. 
 
3. A study on Prognosis among patients with prior CABG and 
without CABG can be undertaken, since many patients present 
with MI following as well as many years after CABG. 
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ANNEXURES 
 
ABBREVIATIONS 
 
CAD  :  Coronary Artery Disease 
ACS  :  Acute Coronary Syndrome  
MI  :  Myocardial Infarction 
STEMI :  ST Elevation Myocardial Infarction  
NSTEMI :  Non ST Elevation Myocardial infarction  
TMT  :  Tread Mill Test 
WC  :  Waist Circumference 
BMI  :  Body Mass Index 
ECG  :  Electrocardiography 
ECHO :  Echocardiogram 
ESC  :  European Society of Cardiology 
LBBB :  Left Bundle Branch Block 
LV  :  Left Ventricle 
MR             :                     Mitral Regurgitation  
CAG : Coronary Angiogram 
DD : Diastolic Dysfunction 
CABG : Coronary Artery Bypass Graft 
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PCI :  Percutaneous   Coronary Intervention 
CRP : C - reactive protein  
CrCl : Creatinine Clearance 
GFR : Glomerular Filtration Rate 
CK – MB : Creatinine kinase MB 
TROP-T : Troponin T 
URL : Upper Reference Limit of Normal. 
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PROFORMA 
Name:                                                       Age:                   Sex: 
Education: 
Address: 
Unit/Ward: 
ID number:     
INFORMANT                 : Self / Other RELATION 
 
PRESENT HISTORY 
Day of onset of the symptoms 
Time of onset of the symptoms 
Treatment obtained prior to admission 
 
PAST & PERSONAL HISTORY 
Diabetes Mellitus    Yes / No  Duration 
Hypertension    Yes / No  Duration 
Angina     Yes / No  Duration 
Myocardial Infarction   Yes / No  Duration 
Heart failure    Yes / No  Duration 
Peripheral Vascular disease  Yes / No  Duration 
Asthma or COPD    Yes / No  Duration 
Dyslipidemia    Yes / No  Duration 
Alcoholism     Yes / No  Duration 
Smoking     Yes / No  Duration 
Medications 
 
FAMILY HISTORY 
Hypertension     Yes/No                  Duration 
Diabetes                                              Yes/No                 Duration 
 Coronary artery disease                      Yes/No                 Duration 
94 
 
PREGNANCY/PUERPERIUM AT PRESENT              Yes /No 
 
VITALS 
Pulse rate   : /min 
Blood Pressure  : 
/ mm Hg Limb  : RUL / LUL Posture: /sitting / Supine 
 
 
ANTHROPOMETRY 
Height   : m 
Weight   : kg 
BMI    : kg / m2 
Waist Circumference       : 
 
CVS    : 
 
Respiratory system : 
 
Abdomen examination : 
 
CNS examination  : 
 
 
INVESTIGATIONS: 
 
COMPLETE HEMOGRAM 
 
Hemoglobin   : g/dL 
Total Count   : cells/cu.mm 
Differential count             : 
RBC Count                       :         cells/cu.mm 
Platelets   : lakhs/cu. mm 
 
 
 
 
  
 
95 
 
BLOOD BIOCHEMISTRY 
 
Random Blood Sugar : mg/dL 
Blood Urea   : mg/dL 
Serum Creatinine  : mg/dl 
Serum sodium                :          meq/l 
Serum potassium            :          meq/l. 
CK MB                            :          IU/ml. 
Troponin                          :          ng/ml. 
Fasting lipid profile         :          mg/dl 
 
LIVER FUNCTION TESTS 
1. Total bilirubin        :         mg/dl.    
2.  AST                    :         IU/L. 
3. ALT                       :       IU/L. 
4. Total proteins         :   grams/dL. 
5. Albumin                 :         grams/dl. 
 
URINE ANALYSIS 
1. ALBUMIN 
2. SUGAR 
3. DEPOSITS 
 
ECG 
 
CHEST XRAY    
 
ECHOCARDIOGRAM 
 
ANGIOGRAM 
 
TMT 
 
CABG 
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NAME    AGE SEX OCCUPATION EDUCATION DURATION OF SYMPTOMS DM SHT CAD DYSLIPIDEMIA PVD ALCOHOLISM SMOKING FAMILY H/O CAD BMI WHR CMS CKMB UNITS/ML TROP T
MADURAI 55 MALE COOLIE NOT EDUCATED  2 DAYS NO NO NO NO NO  OCCASIONAL NO NO 26.7 96 540 143
RANI PREMILA 64 FEMALE FNA 9TH STD 12 HRS 17YRS 14YRS UA,I MONTH NO NO NO NO NO 27.4 94 NEGATIVE NA
GOVINDASAMY 60 MALE FARMER 8TH STD 5 HRS NO 25 YRS CAD,2 MTHS NO NO EX EXSMOKER NO 23.4 94 NEGATIVE NA
RAJA 66 MALE SECURITY NOT EDUCATED 3 DAYS NO NO NO NO NO NO 15 PACK YRS NO 21.7 75 426 NA
RAJENDRAN 45 MALE FARMER 10TH STD 3 DAYS 1YR,6 MTHS NO AWMI,3 MNTHS NO NO NO NO NO 18.3 81 NEGATIVE NA
ELIYAS 40 MALE FARMER 5TH STD 2 DAYS NO NO AWMI,3 MNTHS NO NO EX EXSMOKER YES,MOTHER 20.1 79 NEGATIVE NA
VARAVAN 75 MALE BUSINESS 2ND STD 12 HRS 4 YRS 4YRS AWMI,11YRS NO NO 30 YRS,180 ML 25 PACK YRS NO 22.1 86 296 NA
SIVASUBRAMANI 60 MALE ELECTRICIAN 10 TH STD 1O HRS 10 YRS NO ASMI,10 YRS NO NO NO NO NO 26.7 95 567 NA
YESAIYYA 44 MALE WARD BOY 9TH STD 3 HRS NO 1 YR IWMI ,15 YRS NO NO EX EXSMOKER NO 21 78 771 NA
GOVINDARAJ 46 MALE BUSINESS 8TH STD 4 HRS NO NO NO NO NO NO NO NO 19.4 90 296 NA
GANESAN 42 MALE COOLIE 10 TH STD 2 DAYS NO NO AWMI,2 MTHS NO NO NO NO NO 25.6 101 NEGATIVE NA
PANDIYAN  57 MALE COOLIE 2ND STD  4 DAYS NO NO AWMI,2 MTHS NO NO 10 YRS ,180 ML EXSMOKER NO 18.5 80 NEGATIVE NA
VARADHAN 57 MALE FARMER 5TH STD  3 HRS NO NO NO NO NO 1 YR,180 ML 0.5 PACK YR NO 20.8 78 389 NA
MARIMUTHU 53 MALE MECHANIC 11TH STD 2 DAYS 4 YRS NO NO NO NO NO NO NO 26 87 NEGATIVE NA
JOHNY 55 MALE CONTRACTOR 10TH STD 4 DAYS 15 YRS  8 YRS NO NO NO EX EXSMOKER YES,BROTHER 25.7 101 NEGATIVE NA
SULOCHANA 60 FEMALE HOME MAKER 8TH STD 2 DAYS 1 YR 1 YR NO NO NO NO NO NO 25.3 88 157 NA
PERUMAL 56 MALE CONDUCTOR 10TH STD 4 HRS 3 YRS 3 YRS MI,18 YRS NO NO 25 YRS,90 ML 12.5 PACK YRS NO 23.7 100 190 NA
RAJA 41 MALE DRIVER 12TH STD 3 DAYS NO 5 YRS NO NO PVD,LT LL 15 YRS,180 ML EXSMOKER NO 28.2 108 534 NA
VENKATESAN 57 MALE COOLIE 8 TH STD 3 DAYS NO  1 YR NO NO NO NO NO NO 15.8 88 516 NA
SURESH 35 MALE ELECTRICIAN 9TH STD  6 HRS NO NO ASMI,2 YRS NO NO OCCASIONAL EXSMOKER NO 25.3 94 250 NA
MUNVARDEEN 31 MALE BUSINESS 8TH STD 6 HRS NO NO NO NO NO 10 YRS ,180 ML 5 PACK YRS YES,FATHER 22.9 88 554 NA
KRISHNAMOORTHY 72 MALE SECURITY 7TH STD 3 DAYS 4YRS  4 YRS AWMI,10 YRS NO NO OCCASIONAL OCCASIONAL NO 18.4 81 560 NA
PALAYAM 60 MALE FARMER NOT EDUCATED 4 HRS NO NO NO NO NO NO EXSMOKER NO 18.7 87 201 NA
VENU 63 MALE PROGITHAR NOT EDUCATED 3 DAYS NO 4 YRS NO NO NO NO NO NO 19.5 79 176 NA
SIVARAMAN 46 MALE OT TECHNICIAN 10TH STD 2 DAYS NO NO AWMI, 1 MTH NO NO NO EXSMOKER YES,FATHER 22.6 82 NEGATIVE NA
SHANMUGAM 58 MALE FARMER 8TH STD 3 DAYS NO NO CAD,3 YRS NO NO NO EXSMOKER NO 28 102 NEGATIVE NA
RAMESH 55 MALE BOOK SELLER 8TH STD 12 HRS 15 YRS 15 YRS NO NO NO 15 YRS,180 ML 7.5 PACK YRS NO 20.4 97 2509 NA
THANGAVELU 53 MALE SECURITY 8TH STD 3 DAYS NO NO NO NO NO EX EXSMOKER NO 24.9 99 NEGATIVE NA
THAMBIYAPILLAI 51 MALE SUB INS 10 TH STD 4 DAYS I YR 1 YR NSTEMI,2 MTH NO NO EX EXSMOKER NO 26 101 NEGATIVE NA
KALIYAPERUMAL 58 MALE FIRE SERVICE 10TH STD 5 DAYS 9 YRS 8 YRS IWMI 9 YRS NO NO NO NO NO 19.9 75 NEGATIVE NA
SIVARAMAN 42 MALE COOLIE 5TH STD 10 DAYS NO NO NO NO YES,RT UL 15 YRS,180 ML 10 PACK YRS NO 23.4 90 NEGATIVE NA
K.R.GOVINDHAN 46 MALE ELECTRICIAN 7TH STD 2 HRS NO NO NO NO NO 4 YRS,180 ML 25 PACK YRS NO 27.3 98 217 NA
VITTABAI 65 FEMALE HOME MAKER 5TH STD 1 WEEK 14 YRS 7 YRS YES . 1 YR NO NO NO NO NO 25.8 91 NEGATIVE NA
MUNIYAMMAL 60 FEMALE HOME MAKER NOT EDUCATED 6HRS NO 3YRS NO NO NO NO NO NO 26.5 96 411 NA
MANOHARAN 50 MALE CLEANER NOT EDUCATED 8HRS  NO NO NO NO NO 15 YRS,90 ML 7.5 PACK YRS NO 16.6 72 217 NA
RAVI 42 MALE DRIVER 6TH STD 3 DAYS NO NO NO NO NO 8 YRS,180 ML 4 PACK YRS NO 20.1 76 402 NA
RAJAGURU 49 MALE BUSINESS 7TH STD 4 HRS NO NO NO NO NO NO 15 PACK YRS NO 23.2 82 143 NA
MUBHARAKKHAN 48 MALE ELECTRICIAN 5TH STD 1 DAY NO NEW YES,6 YRS NO NO NO 15 PACK YRS YES,FATHER 26 86 NEGATIVE NEGATIVE
SANTHANAM 54 MALE LOAD MAN NOT EDUCATED 2 DAYS 3 MONTHS 10 YRS YES,3 YRS NO NO EX EXSMOKER NO 24.7 98 NEGATIVE NA
GOVINDASAMY 50 MALE FARMER 10TH STD 3 DAYS NO NO UA,I MONTH NO NO NO NO NO 21 82 NEGATIVE NA
CHANDRASEKAR 66 MALE SUPERVISOR 10 TH STD 2 DAYS NEW NO NO NO NO NO NO NO 24.8 94 164 NA
BALAKRISHNAN 74 MALE PVC 10TH STD 6 DAYS NO NO CAD,6 YRS NO NO NO NO NO 28.5 102 NEGATIVE NA
RAJAGOPAL 58 MALE BUSINESS 10TH STD 5 DAYS NO 20 YRS MI,9 MTHS NO NO NO NO NO 18.7 79 NEGATIVE NA
MEHABUBASHA 54 MALE BIDI ROLLER  NOT EDUCATED 3 DAYS NO NO NO NO NO OCCASIONAL 15 PACK YRS NO 21.4 80 518 NA
VENKATESAN 42 MALE CONTRACTOR 8TH STD 5 HRS NO NO RHD,MS,MR NO NO OCCASIONAL EXSMOKER NO 21.4 87 847 NA
ASAITHAMBI 60 MALE BUSINESS 8 TH STD 4 HRS NO NO NO NO NO NO NO NO 24.4 91 145 NA
SELVABALAJI 27 MALE DRIVER 9 TH STD 1 DAY NO NO CAD,2 WKS NO NO NO 10 PACK YRS NO 22.7 90 230 NA
VIJAYAKUMAR 48 MALE MED.REP BSC 4 DAYS 2 YRS NO NO NO NO 20 YRS,180 ML 15 PACK YRS NO 22 84 421 NA
KALIMUTHU 48 MALE TEA SHOP  NOT EDUCATED 6 HRS NO NO NO NO NO OCCASIONAL OCCASIONAL NO 26 88 500 NA
SUBRAMANI 62 MALE COOLIE 3RD STD 2 DAYS NO NO NO NO NO 15 YRS,180 ML 7.5 PACK YRS NO 23.9 102 NEGATIVE NA
THULASINGHAM 66 MALE SECURITY 8TH STD 1 DAY NO NO NO NO NO NO NO NO 24.3 88 NEGATIVE NA
MANJULA 48 FEMALE HOME MAKER 8 TH STD 8 HRS 6 MONTHS 6 MONTHS YES,6 MTHS NO NO NO NO NO 34.8 108 NEGATIVE NA
GOWRI 55 FEMALE HOME MAKER 8 TH STD 2 DAYS 10 YRS 10 YRS IWMI,6 MTHS NO YES NO NO YES,MOTHER 26.4 93 NEGATIVE NA
OMANIAMMAL 62 FEMALE HOME MAKER 10 STD 1 DAY 23 YRS 9 YRS IPMI,9 YRS NO NO NO NO YES , MOTHER 25.2 86 NEGATIVE NA
DHARMALINGAM 52 MALE FARMER 3RD STD 3 DAYS NO NO PCI, LAD,I MTH NO NO 10 YRS ,180 ML 5  PACKYRS NO 19.3 76 253 NA
RAMADOSS 64 MALE FARMER 10TH STD 2 DAYS 3 MONTHS NO AWMI,1 WK NO NO 15YRS,180ML 15 PACK YRS NO 25.9 94 NEGATIVE NA
KUMAR 63 MALE IRONING 5 TH STD 7 DAYS 10 YRS 1 YR UA,2 MONTH NO NO NO NO NO 20.3 94 NEGATIVE NA
BABU 50 MALE TEA SHOP  1ST STD 3 DAYS NO 1 YR UA, 3 MTHS NO NO NO 25 PACK YRS   NO 25.4 103 NEGATIVE NA
SARAVANAN 42 MALE DRIVER 10 TH STD 2 DAYS 1YR,6 MTHS NO IPMI,14 MTHS NO NO OCCASIONAL 5 PACK YRS NO 23 94 NEGATIVE NA
MOORTHY 45 MALE DRIVER 6 TH STD 2 DAYS NO NO AWMI,2 YRS NO NO OCCASIONAL 20 PACK YRS NO 20.4 96 NEGATIVE NA
KATHAVARAYAN 52 MALE HEALTH INS 8 TH STD 5 DAYS NO NO IPMI,3 MTHS NO NO NO NO NO 26 92 NEGATIVE NA
MOHAMMED IMRAN 56 MALE MECHANIC 10 TH STD 3 DAYS 3 YRS NO  AWMI,,I MTH NO NO NO 15 PACK YRS NO 28.1 101 NEGATIVE NA
BALAMURUGAN 43 MALE DRIVER 10 TH STD 2 DAYS NO 6 MONTHS NSTEMI,1 MTH NO NO OCCASIONAL OCCASIONAL NO 25.7 102 NEGATIVE NA
BALAKRISHNAN 56 MALE TEXTILES 10TH STD  4 DAYS NO 15 YRS NO NO NO NO NO YES,MOTHER 35.3 86 NEGATIVE NA
VARADHACHARI 71 MALE CARPENTER NOT EDUCATED 1 DAY NO NO NO NO NO NO NO NO 24.8 94 352 1494
JEGADEESAN 54 MALE CONTRACTOR 5TH STD 3 DAYS NO 6 MONTHS MI,6 MTHS NO NO OCCASIONAL 15 PACK YRS YES,MOTHER 20.6 67 NEGATIVE NA
HUSSAIN 27 MALE MECHANIC 5TH STD 3 DAYS NO NEW NO NO NO NO NO NO 23.4 92 NEGATIVE NA
CHINNASAMY 70 MALE MECHANIC NOT EDUCATED  4 DAYS NEW NEW NO NO NO 15 YRS,180 ML 10 PACK YRS NO 19.1 80 NEGATIVE NA
SRINIVASAN 53 MALE BUSINESS 10TH STD 3 DAYS 2 YRS 2 YRS HYPOTHYROID NO NO NO NO YES,MOTHER 22.6 86 NEGATIVE NA
GURUSAMY 53 MALE FARMER 10TH STD 2 DAYS NO NO AWMI,3 MNTHS NO NO NO NO NO 18 71 NEGATIVE NA
NATARAJAN 57 MALE TAILOR 8TH STD 15 HRS 15 YRS 1 YR NO NO NO NO NO YES,FATHER,MOTHER 26.7 104 NEGATIVE NA
HARIKRISHNAN 62 MALE APPRAISER BSC.MATHS 4 HRS 1YR,6 MTHS NO NO NO NO NO EXSMOKER NO 24.9 76 23 NA
ARUMUGAM 36 MALE BUSINESS 9TH STD 6 HRS 4 YRS 4YRS NO NO NO EX EXSMOKER YES,MOTHER 28 100 522 NA
SIVANESAN 54 MALE BUSINESS 10TH STD 5 DAYS 8 YRS 8 YRS AWMI,5 YRS NO  NO EX EXSMOKER YES,FATHER 26.3 111 NEGATIVE NA
MANJAPPAN 44 MALE SECURITY 12TH STD 2 DAYS NO NO NO NO NO 10 YRS ,180 ML 15 PACK YRS NO 24.5 96 139 NA
DAMODHARAN 70 MALE PROGITHAR 8TH STD 2 HRS 11 YRS 3 YRS YES,3 MTHS NO NO NO NO NO 23.7 98 NEGATIVE NA
EGAMBARAM 60 MALE STATIONERIES 7 TH STD 2 DAYS NO NO YES . 1 YR NO NO NO 2 PACK YRS NO 18 78 NEGATIVE NA
FRANCIS 65 MALE GOVT,EMPLOYE 8TH STD 2 DAYS NO NO NO NO NO EX EXSMOKER NO 23.4 101 NEGATIVE NA
RAMAMOORTHY 42 MALE BUSINESS 8 TH STD 3 DAYS NO NEW AWMI,1 MTH NO NO NO NO NO 28 94 NEGATIVE NA
KANNIYAMMAL 50 FEMALE HOME MAKER 5TH STD 2 DAYS NEW NEW CA,CX NO NO NO NO YES,MOTHER 26.9 93 NEGATIVE NA
PACHAIYAPPAN 52 MALE COOLIE 5TH STD 2 HRS 3 YRS 1 YR NO NO NO EX EXSMOKER NO 26.9 102 103 NA
JEYASEELAN 45 MALE AUTO DRIVER 9TH STD 3 HRS NO 1 YR,NO DRUGS NO NO NO 3YRS,180ML NO YES,FATHER 19.6 98 179 NA
JAMILABEE 60 FEMALE HOME MAKER NOT EDUCATED 6 HRS NO 3 YRS NO NO NO NO NO NO 23.7 96 607 NA
MOORTHY 45 MALE BUSINESS 9TH STD 6 HRS NO NO NO NO NO OCCASIONAL OCCASIONAL YES,FATHER,SISTER 30.3 92 2001 NA
EKKAMMAL 70 FEMALE COOLIE NOT EDUCATED 1 DAY NO NO NO NO NO NO NO NO 22.1 79 365 NA
MOIDEEN BASHA 64 MALE STORE KEEPER 10TH STD 2 DAYS 5YRS 5YRS YES,6 YRS NO NO NO NO NO 25.7 88 NEGATIVE NA
SEKAR 62 MALE TEA SHOP  4TH STD 4 HRS NO 4 YRS NO NO NO 30 YRS 30 PACK YRS NO 22.9 96 NEGATIVE NA
SURESH 38 MALE REP 8TH STD 12 HRS NO NO NO NO NO YES,5 YRS 5YRS NO 21 97 NEGATIVE NA
PANNEER SELVAM 27 MALE BUSINESS 5TH STD  1 DAY NO NO NO NO NO OCCASIONAL 1.5 PACK YRS NO 17.9 74 129 NA
PATCHAIPILLAI 56 MALE FARMER 8 TH STD 4 DAYS NO NO NO NO NO OCCASIONAL NO NO 25.1 102 NEGATIVE NA
SADHASIVAM 80 MALE BUSINESS 5TH STD  7 DAYS NO NO NO NO N NO NO NO 24 98 NEGATIVE NA
NAGARAJAN 48 MALE BUSINESS 12TH STD 4 DAYS NO 4 YRS IW,RVMI,6 MTS NO NO NO EXSMOKER NO 38.6 88 NEGATIVE NA
RAJASEKAR 49 MALE MECHANIC 10TH STD  4 DAYS NO 15 YRS UA,3 MTHS NO NO 10 YRS ,180 ML 5 PACK YRS YES,FATHER 25.5 93 NEGATIVE NA
NAGARAJAN 56 MALE BUSINESS 12TH STD 4 DAYS NO NEW IWMI,6 MTHS NO NO NO EXSMOKER NO 29.5 107 721 NA
MANOHARAN 43 MALE COOLIE 10TH STD 2 DAYS NO NO NO NO NO OCCASIONAL NO NO 17 66 NEGATIVE NA
JAMES 53 MALE DRIVER 11TH STD 6 DAYS 5 YRS 5 YRS MI,6 MTHS NO NO EX EXSMOKER NO 26.6 103 NEGATIVE NA
ANNAMALAI 60 MALE FARMER 10TH STD 2 DAYS 6 YRS 6YRS IWMI,1 MTH NO NO NO NO NO 31.8 108 786 NA
DINAKARAN 54 MALE FARMER 10TH STD 5 DAYS NO NO NO NO NO 20 YRS,180 ML 15 PACK YRS NO 17.1 86 NEGATIVE NA
GANESAN 52 MALE COOLIE 8TH STD 5 DAYS 10 YRS NO CABG, 10 YRS NO NO 25 YRS,180 ML 15 PACK YRS NO 27 105 NEGATIVE NA
BABYAMMAL 76 FEMALE HOME MAKER 3RD STD 14 HRS 6 MONTHS 6 MONTHS NO NO NO NO NO NO 24.9 91 250 NA
Total
23.876 90.75
TOTAL CHOLESTEROL MG/DL TGL MG/DL LDL MG/DL HDL MG/DL ECG ECHO EF % MR COMPLICATIONS TMT ANGIO PCI CABG DEATH
148 72 NA NA STEMI AWMI,VT MOD LV DYSFN,GRADE 2 DD 42 NO VT NA NA NA NA
NA NA NA NA UA,OLD AWMI  MODERATE  LV DYSFN,GRADE 2 DD 40 NO NA LAD 90,LCX 90,RCA 90 NA CABG
NA NA NA NA UA MODERATE LV DYSFUNCN,GRADE 2 DD 40 TRIVIAL MR FAILURE NA NA NA NA
NA NA NA NA  NSTEMI ,AWMI MODERATE LV DYSFN,GRADE 2 DD 38 MOD MR,AV SCLEROSIS FAILURE NA NA NA NA
NA NA NA NA UA,OLDAWMI MOD LV SYST DYSFN,GRADE 2 DD 43 NO NO NA NA NA NA
NA NA NA NA UA,OLD AWMI MOD LV DYSFN,GRADE 2 DD 44 TRIVIAL MR NO NA DVD NA NA
148 112 142 38 NSTEMI MOD LV DYSFN,GRADE 2 DD 40 AV SCLEROSIS,MILD MR FAILURE NA NA NA NA
141 64 NA NA STEMI,AWMI,AF MOD LV DYSFN,GRADE 1  DD 38 MILD MR AF NA NA NA NA
233 123 NA NA STEMI AWMI,OLD IW MOD LV DYSFN ,GRADE 1 DD 40 NO NA TVD NA CABG
155 142 NA NA STEMI,AWMI MOD.LV DYSFN,GRADE 1DD 43 NO NO NA NORMAL STUDY NA NA
NA NA NA NA UA,OLD IWMI MOD LV DYSFN ,GRADE 1 DD 37 NO NA SVD NA CABG DONE
NA NA NA NA UA,OLD AWMI MOD LV DYSFN,GRADE 1 DD 34 MILD MR NA NA NA NA DIED
140 90 NA NA NSTEMI AWMI MOD LV DYSFN ,GRADE 1 DD 41 MILD TR,PTB NO NA NA NA NA
166 92 NA NA UA MOD. LV DYSFN, GRADE 1 DD 42 NO NA DVD PTCA NA
NA NA NA NA UA MOD.LV DYSFN,GRADE 1DD 37 NO FAILURE NA NA NA NA
178 155 NA NA NSTEMI MOD.SYST.DYSFN,GRADE 1 DD 38 NO NA NA NA NA
172 140 NA NA STEMI,AWMI MODERATE LV DYSFN,GRADE 3 DD 36 NO FAILURE NA NA NA NA
168 152 NA NA STEMI,ALMI MODERATE LV DYSFN 39 NO  FAILURE,PVD NA NORMAL STUDY NA NA
NA NA NA NA STEMI,ASMI MOD LV DYSFN 35 NO NO NA NA NA NA
210 125 NA NA STEMI,ASMI MOD LV DYSFN 40 NO NA SVD PTCA NA
169 164 NA NA STEMI,AWMI, MOD LV DYSFN 38 NO NO NA NA NA NA
NA NA NA NA IP,RVMI,OLD AWMI MOD LV DYSFN,MILD RV DYSFN 37 MILD MR,AV SCLEROSIS FAILURE NA NA NA NA
145 62 NA NA STEMI,IWMI MOD LV DYSFN 40 TRIVIAL TR NA NA NA NA
158 120 NA NA STEMI,AWMI MOD.LV DYSFN 38 TRIV. MR,AV SCLEROSIS,MR NO NA NA NA NA DIED
NA NA NA NA UA MOD LV DYSFN,GRADE 3 DD 36 MILD MR FAILURE NA NORMAL STUDY NA NA
NA NA NA NA UA,OLD AWMI MOD LV DYSFN,GRADE 3 DD 33 DCM,MR FAILURE NA TVD NA NA
200 96 NA NA NSTEMI ,ASMI MODERATE LV DYSFNCN 33 MR MODERATE FAILURE NA TVD NA NA
NA NA NA NA UA MOD LV DYSFN 37 MOD AS,MOD AR NA NA NA NA
NA NA NA NA UA MOD LV DYSFN 41 MOD MR,DCM VT ILL SUST NA LCX 60,RCA 90 NA NA DIED
NA NA NA NA UA,OLD IWMI MOD LV DYSFN 32 TRIVIAL MR NA TVD NA NA
100 NA NA NA UA MOD LV DYSFN 40 TRIVIAL MR NA NA NA NA
162 98 NA NA W      GRADE 2 DD,ADEQ  GRADE  2 DD,NORMAL SYST.FUNCN 58 NO UA NA NA NA NA
NA NA NA NA UA NORMAL LV FUNCN,GRADE 2DD 58 NO NO STRONGLY +VE LAD,70,PROX RCA 70 NA NA
149 72 NA NA               GRADE 2 DD,AD  GRADE  1 DD,NORMAL SYST.FUNCN, 57 NO PULM,EDEMA NA TVD NA NA
165 112 NA NA STEMI,IW,PW,LW NORMAL LV FUNCN,GRADE 1 DD 69 NO NA NA NA NA
146 86 NA NA STEMI,IWMI NORMAL LV FUNCN,GRADE 1 DD 58 NO NA NA NA NA
148 79 NA NA STEMI,IWMI NORMAL LV FN,GRADE 1 DD 62 TRIVIAL MR NA NA NA NA
168 131 NA 40 UA NORMAL LV FUNCN,GRADE 1 DD 56 NO NO STRONGLY +VE PROX.LAD(90),DISTAL RCA(60) PROXLAD NA
NA NA NA NA UA NORMAL LV FUNCN,GRADE 1DD 62 MILD NO NA NA NA NA
NA NA NA NA UA NORMAL LV FUNCN, GRADE 1 DD 61 NO NA TVD NA NA
141 92 NA NA NSTEMI AWMI NORMAL LV FUNCN,GRADE 1 DD 60 MILD MR, AV SCLEROSIS  NA NA NA NA
NA NA NA NA UA NORMAL SYST FUNCN,GRADE 1 DD 58 NO NO NA NA NA NA DIED
143 102 NA NA UA,OLD AWMI NORMAL SYST.FUNCN,GRADE 1 DD 67 TRIVIAL MR SA NODE DYSFN NA NA NA NA
NA NA NA NA STEMI,IW,PW,RVMI  NORMAL SYST.FUNCN,NO DD 56 NO NO NA NA NA NA
148 139 NA NA STEMI,RBBB,IWMI NORMAL LV FUNCN 60 MS,MR,AR,MOD PHT NA NA NA NA
164 80 NA NA STEMI,IW,PW,RVMI NORMAL LV FUNSN 55 TRIVIAL MR NA NA NA NA
170 NA NA NA STEMI , ALMI NORMAL LV FUNCN 65 NO NA MID LAD 70 NA NA
205 81 NA NA STEMI,IWMI NORMAL LV FN 60 RHD,MS,MR NA NA NA NA
156 125 NA NA IW,PWMI NORMAL LV FN 64 NO NO NA NA NA NA
NA NA NA NA UA NORMAL SYST. FUNCN 67 NO UA NA LAD,50,PROX RCA 70 NA NA
NA NA NA NA UA,LBBB NORMAL SYST. FUNCN 58 NO NA LAD 50,RCA 50 NA NA
149 105 NA NA OLD IWMI,UA NORMAL LV SYST.FUNCN 65 NO AF NA NORMAL STUDY NA NA
NA NA NA NA UA,OLD IWMI NORMAL LV FUNCN 65 NO NA SVD NA NA
NA NA NA NA UA,OLD IPMI NORMAL LV FUNCN 55 NO NA TVD NA NA
149 151 NA NA NSTEMI IWMI NORMAL LV FUNCTION 60 NO NA NA NA NA
NA NA NA NA UA NORMAL LV FUNCN 60 NO NA NA NA NA
NA NA NA NA UA,CHB,PPI NORMAL LV FUNCTION  62 TRIVIAL MR CHB,PPI NA NA NA NA
NA NA NA NA UA NORMAL LV FUNCN 60 NO UA NA NA NA NA
NA NA NA NA UA NORMAL LV FUNCN 71 TRIVIAL MR NA DVD NA NA
NA NA NA NA UA NORMAL LV FUNCN 60 NO NA NA NA NA
NA NA NA NA UA,OLD IWMI NORMAL LV FUNCN 68 NO NA NA NA NA
NA NA NA NA UA,OLD AWMI NORMAL LV FUNCN 57 NO NA SVD PTCA NA
NA NA NA NA UA NORMAL LV FUNCN 58 NO NA TVD PTCA NA
NA NA NA NA UA NORMAL LV FUNCTION 62 NO POSITIVE DVD PTCA NA
NA NA NA NA NSTEMI IP,LWMI NORMAL LV FUNCN 65 NO NA NA NA NA
NA NA NA NA UA NORMAL SYST. FUNCN 60 TRIVIAL MR NA LCX 70,RCA 95 PTCA NA
NA NA NA NA UA NORMAL LV FUNCN 56 NO NO NA NA NA NA
NA NA NA NA UA NORMAL LV FN 58 NO NO NA NA NA NA
NA NA NA NA UA NORMAL LV FUNCN 59 NO POSITIVE DVD NA NA
NA NA NA NA UA NORMAL LV FN 60 AV SCLEROSIS,MILD AR NA TVD PTCA NA
NA NA NA NA UA NORMAL LV FUNCTION 70 NO NA SVD NA NA
224 134 154 43 STEMI,ANT.WALL MILD LV SYST.DYSFUNCN,GRADE 2 DD 47 NO UA NA DVD NA NA
245 181 NA NA STEMI,AWMI MILD SYST. DYSFN,GRADE 2 DD 47 RV DILATED NA NA NA NA
NA NA NA NA UA,OLD AWMI MILD LV DYSFN,GRADE 2 DD 46 NO NO  NA NA NA NA
152 145 NA NA STEMI,ASMI MILD LV DYSFN.GRADE 1 DD 49 NO NA SVD PTCA NA
NA NA NA NA UA MILD LV DYSFUNCN,GRADE 1 DD 45 AV SCLEROSIS,MILD MR,AR UA NA TVD NA NA
NA NA NA NA UA,OLD IWMI MILD LV SYST.DYSSFUNCN,GRADE 1 DD 50 NO NA NA NA NA
NA NA NA NA UA,LBBB MILD LV DYSFN , GRADE 1  DD 55 NO NO NA NA NA NA
NA NA NA NA UA MILD LV DYSFN,GRADE 1 DD 47 NO NO NA NA NA NA
177 106 NA NA UA MILD LV DYSFN,GRADE 1 DD 50 NO NA DVD NA NA
154 183 NA NA STEMI,AWMI MILD LV DYSFN , GRADE 3 DD 52 MILD MR,MILD TR,MILD AR FAILURE NA NA NA NA
109 NA NA 41 STEMI,IW,PW MILD LV SYST.DYSFUNCN,NO DD 52 NO NO NA NA NA NA
128 216 NA NA STEMI,IWMI,PW MILD LV DYSFN,NO DD 46 MILD MR, AV SCLEROSIS  MOBITZ TYPE 2 BK NA NA NA NA
148 250 NA NA STEMI,AWMI MILD SYST. DYSFN 52 NO NA NA NA NA
128 94 NA NA IWMI,RVMI,CHB MILD LV DYSFN 53 AV SCLEROSIS,MILD TR CHB,PPI NA NA NA NA
NA NA NA NA UA MILD LV DYSFUNCN 50 NO NO NA NA NA NA
NA NA NA NA UA MILD LV DYSFNCN,DCM 45 TRIVIAL,AR + DCM NA NA NA NA
NA NA NA NA UA  MILD SYST.DYSFNCN 49 NO NA NA NA NA
143 68 NA NA NSTEMI AWMI MILD SYST. DYSFN 54 NO NO NA NA NA NA
518 152 NA NA UA,LBBB MILD LV DYSFN,NO DD 45 TRIVIAL MR UA NA NA NA NA
NA NA NA NA UA MILD LV DYSFN 45 TRIVIAL MR NA NA NA NA
NA NA NA NA UA MILD LV DYSFN 50 NO NA SVD NA NA
NA NA NA NA UA MILD LV DYSFN 50 NO NO NA NA NA NA
209 164 NA NA NSTEMI,ASMI MILD LV DYSFN 48 MILD MR NO NA NA NA NA
NA NA NA NA UA MILD LV DYSFN 46 NO NO NA SVD NA NA
NA NA NA NA UA,LBBB MILD SYST. DYSFN 50 NO NO NA DVD NA NA
180 152 110 40 NSTEMI IWMI MILD LV DYSFN 50 NO NA LAD 50,RCA 50 NA NA
NA NA NA NA UA,LBB,LVH SEVERE LV DYSFUNCTION,GRADE 2 DD 30 MR MOD ‐SEVERE,TR MILD ,L DCM,AF NA NA NA NA
NA NA NA NA UA SEVERE LV DYSFUNCTION,GRADE 3 DD 30 MILD MR, MOD PHT DCM NA LAD 90,LCX 90  NA CABG, 10 YRS DIED
158 121 NA NA NSTEMI SEVERE LV DYSFN,GRADE 3 DD 30 NO FAILURE,DCM NA NA NA NA
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